Patients are eligible for the study if all of the following are true: (i) Hospitalised (ii) SARS-CoV-2 infection (suspected or confirmed) (iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial In addition, if the attending clinician believes that there is a specific contra-indication (see Appendix 2, section 8.2) to one of the active drug treatment arms, then the patient will not be excluded from randomisation to that arm.

Patients are eligible for the study if all of the following are true: (i) Hospitalised (ii) SARS-CoV-2 infection (suspected or confirmed) (iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial In addition, if the attending clinician believes that there is a specific contra-indication (see Appendix 2, section 8.2) to one of the active drug treatment arms, then the patient will not be excluded from randomisation to that arm.

Patients are eligible for the study if all of the following are true: (i) Aged at least 18 years (ii) Hospitalised (iii) SARS-CoV-2 infection (suspected or confirmed) (iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial In addition, if the attending clinician believes that there is a specific contra-indication (see Appendix 2, section 8.2) to one of the active drug treatment arms, then the patient will not be excluded from randomisation to that arm.

Patients are eligible for the study if all of the following are true: (i) Aged at least 18 years (ii) Hospitalised (iii) SARS-CoV-2 infection (suspected or confirmed) (iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial In addition, if the attending clinician believes that there is a specific contra-indication (see Appendix 2, section 8.2) to one of the active drug treatment arms, then the patient will not be excluded from randomisation to that arm.